This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.
MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) was featured in BioMedWire editorial coverage highlighting the growing demand for real-time, noninvasive impairment detection technologies, with the company positioned as a differentiated player leveraging artificial intelligence and voice analysis to identify intoxication from brief speech recordings. The editorial underscores the limitations of conventional detection tools such as breathalyzers, blood draws and urine testing, noting MindBio’s focus on scalable, real-time assessment across multiple substances for potential applications in workplace safety, law enforcement, healthcare and public health.
The coverage also places MindBio within the broader AI-powered healthcare ecosystem alongside Spectral AI (NASDAQ: MDAI), Nano-X Imaging (NASDAQ: NNOX), NVIDIA (NASDAQ: NVDA) and Caris Life Sciences (NASDAQ: CAI), pointing to accelerating adoption of machine learning across diagnostics, imaging and precision medicine. MindBio’s voice-based platform is described as targeting a substantial workplace safety and substance testing opportunity, with its multisubstance detection capabilities potentially offering a meaningful advancement in how impairment is identified and managed at scale.
To view the full press release, visit https://ibn.fm/e8g7Y
About MindBio Therapeutics Corp.
MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN